Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HSK7653 in Renal Impairment
NCT05497297Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cofrogliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 672 hours, Area Under the Plasma Concentration-Time Curve from Zero to Last Quantifiable Concentration at 672 hours and 1 more. Started Aug 2022; status: completed.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05497297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497297.